TrialJournal for immunotherapy of cancer2022

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.

Alexey Revenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.